Effectiveness of Interventions for Hepatitis B and C: A Systematic Review of Vaccination, Screening, Health Promotion and Linkage to Care Within Higher Income Countries

AbstractViral hepatitis is a significant global health concern, particularly within low-middle income countries. Diseases historically affecting low-middle income countries, such as viral hepatitis, have become increasingly prevalent within high-income countries due to globalisation and mass international migration. High prevalence of viral hepatitis in migrant populations is of particular concern due to the associated morbidity and mortality, as well as the increased risk of vertical and horizontal transmission in the community. This is compounded by the asymptomatic nature of hepatitis, meaning many of those affected are unaware of their infection status. Long-term effects of viral hepatitis can include liver cirrhosis, liver cancer and liver failure. Therefore, the health needs of vulnerable migrants within high-income countries due to issues associated with viral hepatitis require attention. This includes assessment of measures such as targeted health education, increased screening, linkage to appropriate treatment and follow-up care. Additionally, it is necessary to address migrant healthcare barriers, such as language, economic and social barriers. It is imperative that vulnerable migrant groups gain appropriate access to health services to prevent disease transmission and the widening of health-related disparities within high-income countries.
Source: Journal of Community Health - Category: International Medicine & Public Health Source Type: research

Related Links:

(STOCKHOLM) — Americans Harvey J. Alter and Charles M. Rice and British-born scientist Michael Houghton won the Nobel Prize for medicine on Monday for their discovery of the hepatitis C virus, a major source of liver disease that affects millions worldwide. Announcing the prize in Stockholm, the Nobel Committee noted that the trio’s work identified a major source of blood-borne hepatitis that couldn’t be explained by the previously discovered hepatitis A and B viruses. Their work, dating back to the 1970s and 1980s, has helped saved millions of lives, the committee said. “Thanks to their discovery, ...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized News News Desk wire Source Type: news
Non-alcoholic fatty liver disease is the most common cause of liver disease in the United States, and is estimated to affect up to a quarter of adults in the world. It is defined by excess fat accumulating in the liver and usually occurs in people with obesity, high blood sugars (diabetes), abnormal cholesterol or triglyceride levels, or high blood pressure. These disorders often run together and as a group are called metabolic syndrome. The “non-alcoholic” part of “non-alcoholic fatty liver disease” is important to distinguish it from alcohol-related liver disease, which can also cause excess liver...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Diet and Weight Loss Digestive Disorders Source Type: blogs
AbstractThe World Health Organisation, in its 2019 progress report on HIV, viral hepatitis and STDs indicates that 257 million people are afflicted with chronic HBV infections, of which, 1 million patients lose their lives every year due to HBV related chronic liver diseases including serious complications such as liver cirrhosis and hepatocellular carcinoma. The course of HBV infection and associated liver injury depend on several host factors, genetic variability of the virus, and the host viral interplay. The challenge of medical science is the early diagnosis/identification of the potential for development of fatal com...
Source: Gut Pathogens - Category: Microbiology Source Type: research
It turns out that many more people than just boomers can benefit from testing for hepatitis C, a viral infection of the liver that often causes no symptoms. If you’re a member of the baby-boom generation (born between 1946 and 1964), your doctor may have already recommended the test. But those born before or after those years may not have known about the test unless they had a risk factor for hepatitis C, such as a history of intravenous drug use. A new guideline is changing this approach. Why the different recommendations for baby boomers? In 2012–2013, the CDC and the US Preventive Services Task Force (USPSTF...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Digestive Disorders Health Infectious diseases Men's Health Sexual Conditions Women's Health Source Type: blogs
ConclusionA substantial further reduction in cases of HCC requires a wider application of universal HBV vaccination and effective treatment of HBV- and HCV-related chronic hepatitis and cirrhosis, more effective campaigns to favor correct dietary habits and reduce alcohol consumption and the intensification of studies on HCC pathogenesis for future optimized prevention strategies.
Source: Infection - Category: Infectious Diseases Source Type: research
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) and liver cirrhosis worldwide. In spite of the numerous advances in the treatment of CHB, drugs and vaccines have failed because of many factors like complexity, resistance, toxicity, and heavy cost. New RNA interference (RNAi)-based technologies have developed innovative strategies to target Achilles' heel of the several hazardous diseases involving cancer, some genetic disease, autoimmune illnesses, and viral disorders particularly hepatitis B virus (HBV) infections. Naked siRNA delivery has serious challenges including failure to cross ...
Source: IET Nanobiotechnology - Category: Nanotechnology Source Type: research
Authors: Kırdar S, Yaşa MH, Sayan M, Aydın N Abstract Chronic hepatitis B (CHB) is an important public health problem affecting over 240 million people all around the world. The aim of the treatment in chronic hepatitis B is to prevent progression to cirrhosis and liver cancer. Interferons (standard and peginterferon) (Peg-IFN) and nucleoside/nucleotide analogues (NAs) are widely used in the treatment of CHB. The use of long-term therapy can however result in drug resistant mutations, which can lead to treatment failure. In patients with chronic hepatitis B, in addition to primary drug resistance mutations in th...
Source: Mikrobiyoloji Bulteni - Category: Microbiology Tags: Mikrobiyol Bul Source Type: research
CONCLUSION: Hepatitis B vaccine is the mainstay of hepatitis B prevention. Safe injection practices, blood safety and promoting wider access to monitoring and screening, care and treatment services for hepatitis B are the best guarantees to prevent and control this disease. PMID: 31060884 [PubMed - as supplied by publisher]
Source: Revue d Epidemiologie et de Sante Publique - Category: Epidemiology Tags: Rev Epidemiol Sante Publique Source Type: research
Tingxin Wu1,2, Fenglei Li1,2, Yongyan Chen1,2, Haiming Wei1,2, Zhigang Tian1,2, Cheng Sun1,2,3* and Rui Sun1,2* 1Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Molecular Medicine, School of Life Sciences, University of Science and Technology of China, Hefei, China 2School of Life Science, Institute of Immunology, University of Science and Technology of China, Hefei, China 3Transplantation and Immunology Laboratory, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China The ability of ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study was supported in part by the National Cancer Center Research and Development Fund (25-A-7 and 28-A-8); Health and Labor Science Research Grants for Clinical Research, Japan; and joint research funding from Takeda Pharmaceutical Co, Ltd.; Noile-Immune Biotech Inc.; Ono Pharmaceutical Co., Ltd.; BrightPath Biotherapeutics Co., Ltd.; and Sysmex Co., Ltd. This study was performed as part of a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan. Conflict of Interest Statement TN, TS, and TY ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cirrhosis | Education | Hepatitis | Hepatitis B | Hepatitis Vaccine | International Medicine & Public Health | Liver | Universities & Medical Training | Urology & Nephrology | Vaccines